key: cord-0706989-y26z05eu authors: Abbas, Mohammad; Verma, Sushma; Verma, Shrikant; Siddiqui, Sahabjada; Khan, Faizan H.; Raza, Syed T.; Siddiqi, Zeba; Eba, Ale; Mahdi, Farzana title: Association of GSTM1 and GSTT1 gene polymorphisms with COVID‐19 susceptibility and its outcome date: 2021-06-12 journal: J Med Virol DOI: 10.1002/jmv.27076 sha: 6ceb355e89a702f4f0537675a217ec43ae07580f doc_id: 706989 cord_uid: y26z05eu Coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection has become a global health issue and develops into a broad range of illnesses from asymptomatic to fatal respiratory diseases. SARS‐CoV‐2 infection is associated with oxidative stress that triggers cytokine production, inflammation, and other pathophysiological processes. Glutathione‐S‐transferase (GST) is an important enzyme that catalyzes the conjugation of glutathione (GSH) with electrophiles to protect the cell from oxidative damage and participates in the antioxidant defense mechanism in the lungs. Thus, in this study, we investigated the role of GSTM1 and GSTT1 gene polymorphism with COVID‐19 susceptibility, as well as its outcome. The study included 269 RT‐PCR confirmed COVID‐19 patients with mild (n = 149) and severe (n = 120) conditions. All subjects were genotyped for GSTM1 and GSTT1 by multiplex polymerase chain reaction (mPCR) followed by statistical analysis. The frequency of GSTM1(−/−), GSTT1(−/−) and GSTM1(−/−)/GSTT1(−/−) was higher in severe COVID‐19 patients as compared to mild patients but we did not observe a significant association. In the Cox hazard model, death was significantly 2.28‐fold higher in patients with the GSTT1(−/−) genotype (p = 0.047). In combination, patients having GSTM1(+/+) and GSTT1(−/−) genotypes showed a poor survival rate (p = 0.02). Our results suggested that COVID‐19 patients with the GSTT1(−/−) genotype showed higher mortality. emerged as a new challenge for the medical sciences. It has been considered a pandemic by the World Health Organization (WHO) from March 11, 2020, onwards. 1 The pathogenesis of COVID-19 and its cause of severity are still poorly understood. SARS-CoV-2 is associated with oxidative stress (OS) that triggers cytokine production, inflammation, and other pathophysiological activities. 2 OS is defined as the disturbance of the antioxidant and prooxidant balance in a biological system. 3 During OS, highly reactive oxygen/nitrogen Mohammad Abbas and Sushma Verma contributed equally to this study as first authors. species (RONS) are produced such as hydroxyl, superoxide anion, nitric oxide, and nitrosyl anion, which target various cells and damage DNA, proteins, and lipids, leading to the pathogenesis of respiratory viral infections including SARS-CoV-2 infections. [3] [4] [5] Delgado-Roche and Mesta, 5 suggested that OS coupled with innate immunity affects the onset of severe lung injury in COVID-19 patients and stimulates transcription factors, such as NF-kB, resulting in an exacerbated pro-inflammatory host response. However, the COVID-19 patients with pre-existing conditions such as diabetes, hypertension, and pulmonary, cardiac, and kidney diseases are at a higher risk of developing a severe infection. [6] [7] [8] [9] Glutathione S-transferases (GSTs) are a superfamily of multifunctional isoenzymes that catalyzes glutathione conjugation with electrophilic compounds, resulting in the cellular detoxification of several endogenous and exogenous compounds. 10 GSTs play an important role in the detoxification of different carcinogens, drugs, and against various types of cellular oxidative damage. 11 The GST enzyme contributes to different interindividual activity in response to clearance of oxidative stress products. 12 In mammalian tissue, eight distinct classes of the cytosolic GST enzymes have been recognized such as alpha (α)-GSTA, mu (μ)-GSTM, pi (π)-GSTP, omega (ω)-GSTO, theta (θ)-GSTT, sigma (σ)-GSTS, kappa (κ)-GSTK), and zeta (ζ)-GSTZ. 13 The μ (GSTM1: MIM: 600436) and θ (GSTT1: MIM: 138350) members are the most common variant of GST genes, which are located on chromosome 1p13.3 and 22q11.23, respectively. 14, 15 The homozygous deletion (null genotype) of the GSTM1 (GSTM1 −/− ) and GSTT1 (GSTT1 −/− ) genes are associated with the loss of enzyme activity and increase the risk of several oxidative stress associated multifactorial diseases including cardiovascular and respiratory diseases. [16] [17] [18] [19] [20] Thus, in this study, we investigated the association of GSTM1 and/or GSTT1 polymorphisms with COVID-19 susceptibility as well as its outcome in the North Indian population. Genomic DNA was extracted from peripheral blood samples by using a Commercially Available Kit (Macherey-Nagel) and the quality/quantity of DNA was assessed by using a spectrophotometer and gel electrophoresis checked on 1% agarose gel and quantified in a biophotometer (Eppendorf). GSTM1 and GSTT1 null genotypes were detected by using multiplex polymerase chain reaction (mPCR) using specific primers: F-5′ Demographic and clinical data were compared with genotypes using χ2 analysis and Fisher's exact test. Allele and genotype frequencies in mild and severe cases were compared using a 2 × 2 contingency table by Fisher's exact test. The odds ratio (OR) at 95% confidence interval The distribution of GSTM1 and GSTT1 genotypes in mild and severe patients is shown in Table 1 . The frequency of GSTM1 −/− and GSTT1 −/− (null genotypes) was higher among severe patients than in mild (13.3% vs. 10.7%; 14.2% vs. 10.7%, respectively) that showed the corresponding marginal increased risk of severity with null genotypes (Table 1) . Individuals with a combination of two null genotypes (GSTM1 −/− /GSTT1 −/− ) showed a 3.91-folds higher risk of severity due to COVID-19 infection when adjusted with age, sex, hypertension, and diabetes (Table 1) . However, GSTM1/GSTT1 polymorphism was not shown to have a significant association with the severity of the COVID-19 (p > 0.05, Table 1) . We have also shown the distribution of GSTM1 and GSTT1 genotypes with demographic and clinical data in COVID-19 severe patients. But none of the demographic and clinical parameters showed a significant association with GSTM1/GSTT1 polymorphism (p > 0.05, Table 2 ). The follow-up duration for all patients was 1 month. During the study period, 11.9% of patients succumbed to death. The median survival had not been reached and the overall mean survival time was 27.79 days. The association of GSTM1 and GSTT1 genotypes with overall survival were analyzed by Cox proportional hazards model, adjusted for age, sex, hypertension, and diabetes are shown in Table 3 . There was a significant increase in the hazard of death to 2.28 among patients with GSTT1 −/− when compared with patients having the GSTT1 +/+ genotype (95% CI = 1.013-5.141; p = 0.047). However, there was no significant association with GSTM1 genotypes (p = 0.853). In the combined effect of GSTM1 and GSTT1, individuals with GSTM1 +/+ and GSTT1 −/− genotypes showed a significantly 2.72folds higher risk of death due to COVID-19 (95% CI = 1.172-6.295; p = 0.02). The Kaplan-Meier function for survival in cases with GSTM1 and GSTT1 genotypes is shown in Figure 2 . In the Kaplan-Meier curve, GSTT1 −/− was associated with poor overall survival (log-rank, p = 0.020, Figure 1B ). In addition, the combined effect showed that both genes have an impact on survival. Patients with GSTM1 +/+ /GSTT1 −/− genotype showed significantly poor overall survival as compared to patients having GSTM1 +/+ /GSTT1 +/+ genotypes (log-rank, p = 0.015, Figure 1C ). T A B L E 1 Genotype frequencies of GSTM1 and GSTT1 and their association with severity of COVID-19 Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review Molecular immune pathogenesis and diagnosis of COVID-19 What is oxidative stress? COVID-19 infection and oxidative stress: an under-explored approach for prevention and treatment Oxidative stress as key player in severe acute respiratory syndrome coronavirus (SARS-CoV) infection Cancer Guidelines. The European Society of Gynaecological Oncology (ESGO) COVID-19 and kidney disease: molecular determinants and clinical implications in renal cancer COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study COVID-19 and asthma: reflection during the pandemic Genetic polymorphism in glutathione transferases (GST): population distribution of GSTM1, T1, and P1 conjugating activity Glutathione S-transferase polymorphisms and their biological consequences Glutathione S-transferase is a good biomarker in acrylamide induced neurotoxicity and genotoxicity Structure, function and evolution of glutathione transferases: implications for classification of non-mammalian members of an ancient enzyme superfamily Glutathione S-transferases: gene structure and regulation of expression Glutathione S-transferase polymorphisms and survival in primary malignant glioma Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases Glutathione transferases Relevance of the deletion polymorphisms of the glutathione S-transferases GSTT1 and GSTM1 in pharmacology and toxicology Glutathione S-transferase polymorphisms: cancer incidence and therapy Interactions of GST polymorphisms in air pollution exposure and respiratory diseases and allergies Clinical Management Protocol: COVID-19. Government of India, Ministry of Health and Family Welfare, Directorate General of Health Services (EMR Division) Impact of I/D polymorphism of angiotensin-converting enzyme 1 (ACE1) gene on the severity of COVID-19 patients Differential roles of 3H-1,2-dithiole-3-thione-induced glutathione, glutathione S-transferase and aldose reductase in protecting against 4-hydroxy-2-nonenal toxicity in cultured cardiomyocytes The morbidity and mortality of COVID-19 are correlated with the Ile105Val glutathione S-transferase P1 polymorphism An evidence for correlation between the glutathione Stransferase T1 (GSTT1) polymorphism and outcome of COVID-19 Clinical features of patients infected with 2019 novel coronavirus in Wuhan Redox biology of respiratory viral infections Effect of melatonin supplementation and cross-fostering on renal glutathione system and development of hypertension in spontaneously hypertensive rats COVID-19: melatonin as a potential adjuvant treatment Glutathione S-transferase genotypes modify lung function decline in the general population: SAPALDIA cohort study Association between glutathione S-transferase gene M1 and T1 polymorphisms and chronic obstructive pulmonary disease risk: a meta-analysis The authors declare that there are no conflict of interests.